Respiratory News and Research

RSS

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral and cancer mutations are to be reported in a poster presentation titled "Detection of novel HPV mutations and chromosomal number imbalance (CNI) in oropharyngeal and laryngeal cancer using next-generation sequencing (NGS)" (Abstract #6072) at the American Society of Clinical Oncology Annual Meeting (ASCO 2014) being held from May 30 through June 3, 2014 in Chicago.

31 May 2014

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet.

31 May 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

U.S. Court awards Teva favorable decision for generic Celebrex

Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day "first-to-file" exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules.

31 May 2014

Researchers develop virtual platform that measures level of addiction of smokers

In Mexico, 21.7 percent of the population smokes, which is associated with 95 percent of  lung cancer cases and the development of 29 more different conditions.

31 May 2014

Newron Pharmaceuticals submits safinamide NDA to FDA

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area with a long experience in respiratory disease therapies, woman care and primary care, announce that the New Drug Application (NDA) for safinamide was submitted today to the US Food and Drug Administration (FDA).

30 May 2014

CHLA receives $1.5M gift from Walgreens to support pediatric clinical care, research programs

Walgreens, the country's largest drugstore chain, has made a $1.5 million gift to support pediatric clinical care and research programs at Children's Hospital Los Angeles (CHLA).

30 May 2014

Midwest allergist records highest mold count for the 2014 allergy reporting season

The official allergy count for the Midwest today recorded the highest count for mold in the 2014 allergy recording season.

29 May 2014

Study reveals how BTK mutation triggers drug resistance in CLL patients

A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug.

29 May 2014

Synexus starts new state of art clinical trial centre in Bochum, Germany

On 28th May, 2014, Synexus officially opened a new state of the art clinical trial centre in Bochum, Germany.

From AES - Accelerated Enrollment Solutions 29 May 2014

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

29 May 2014

Researchers take another promising step toward developing universal antidote for snakebite

A team of researchers, led by Dr. Matthew Lewin of the California Academy of Sciences and Dr. Stephen P. Samuel of Trinity College Dublin, Ireland has taken another promising step toward developing a universal antidote for snakebite.

29 May 2014

Ebola research: an interview with Professor Easton, University of Warwick

Ebola virus belongs to a group of viruses that have been known for some time. It was first isolated as a result of an infection in a primate, in a monkey colony, in monkeys that were being used for research in the Philippines.

28 May 2014

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina™, a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).

28 May 2014

Allergists warn e-smokers of unknown risks

Caveat emptor - or "buyer beware" holds true when it comes to the unknown health effects of e-cigarettes. An article in the June issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI), examines risks, including the ongoing dependence on nicotine and the dual use of e-cigarettes and regular cigarettes.

27 May 2014

Study shows positive effects of using hypertonic saline on infants with bronchiolitis

A team of researchers, led by physicians from Children's Hospital Los Angeles, have found that infants with bronchiolitis who were treated with inhaled hypertonic saline in the emergency department (ED) were less likely to require admission to the hospital compared to infants treated with normal saline.

26 May 2014

New report raises important questions about transcranial direct current stimulation

Over the past several decades, neurostimulation techniques such as transcranial direct current stimulation (tDCS) have gradually gained favour in the public eye. In a new report, published yesterday in the prestigious scientific journal Neuron, IRCM ethics experts raise important questions about the rising tide of tDCS coverage in the media, while regulatory action is lacking and ethical issues need to be addressed.

23 May 2014

New project aims at saving lives of mothers, newborns in developing countries

Grand Challenges Canada, funded by the Government of Canada, today announces investments of $12 million in projects worldwide, aimed squarely at improving the health and saving the lives of mothers, newborns and children in developing countries.

22 May 2014

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).

22 May 2014

Respiratory News and Research

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

U.S. Court awards Teva favorable decision for generic Celebrex

Researchers develop virtual platform that measures level of addiction of smokers

Newron Pharmaceuticals submits safinamide NDA to FDA

CHLA receives $1.5M gift from Walgreens to support pediatric clinical care, research programs

Midwest allergist records highest mold count for the 2014 allergy reporting season

Study reveals how BTK mutation triggers drug resistance in CLL patients

Synexus starts new state of art clinical trial centre in Bochum, Germany

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Researchers take another promising step toward developing universal antidote for snakebite

Ebola research: an interview with Professor Easton, University of Warwick

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

Allergists warn e-smokers of unknown risks

Study shows positive effects of using hypertonic saline on infants with bronchiolitis

New report raises important questions about transcranial direct current stimulation

New project aims at saving lives of mothers, newborns in developing countries

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News